ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer
KEYNOTE-355 Mixed On PFS; Still Waiting On OS
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
